LXRXLexicon Pharmaceuticals, Inc.
What is the market doing?
No clear lean: rangebound and heavily shorted.
Rangebound, no clear trend. Oversold (RSI 28). Price is −7% vs its 200-day average.
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How LXRX is trading
Lexicon Pharmaceuticals, Inc. is +40% over the past year while the S&P 500 is +18%: 22 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −6.6%
vs 200-day average · below trend, but not far
- RSI (14)
- 28
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 33%
Below its 52-week high
Details›
- Last close2026-10-09
- $1.67
- 1 monthS&P 500 +2.7%
- −17%
- 1 yearS&P 500 +18%
- +40%
- 5 yearsS&P 500 +88%
- −63%
- vs 50-day average$2.14
- −22%
- 52-week high
- $2.50
- 52-week low
- $1.14
- Annualised volatility
- 110%
| Year | Return |
|---|---|
| 2026 (year to date) | +45% |
| 2025 | +55% |
| 2024 | −52% |
| 2023 | −20% |
| 2022 | −52% |
| 2021 | +15% |
| 2020 | −18% |
| 2019 | −37% |
| 2018 | −33% |
| 2017 | −29% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 7 of 10 | +12% |
| Feb | 10 | 5 of 10 | +0.16% |
| Mar | 10 | 4 of 10 | −7.8% |
| Apr | 10 | 4 of 10 | +0.02% |
| May | 10 | 5 of 10 | +8.1% |
| Jun | 10 | 8 of 10 | +7.8% |
| Jul | 11 | 5 of 11 | −2.5% |
| Aug | 11 | 3 of 11 | −2.4% |
| Sep | 11 | 4 of 11 | +5.7% |
| Oct | 11 | 5 of 11 | −2.9% |
| Nov | 10 | 5 of 10 | −4.4% |
| Dec | 10 | 3 of 10 | +10% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.